Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 1;11:600227. doi: 10.3389/fgene.2020.600227

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Liu, Yi, Liu, Chen, Zhang, Zhou, Zhan, Zhao, Morales, Zhao and Zeng.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The effect of CDK6 expression on overall survival in non-APL AML patients. (A) Kaplan–Meier analysis of OS in chemotherapy only group in non-APL AML patients [CDK6high (n = 36) vs. CDK6low (n = 36): p = 0.76] (cut point: median CDK6 expression level). (B) Kaplan–Meier analysis of OS in auto-/allo-HSCT group in non-APL AML patients [CDK6high (n = 31) vs. CDK6low (n = 32): p = 0.79] (cut point: median CDK6 expression level). (C) Kaplan–Meier analysis of OS in chemotherapy only group in cytogenetically normal AML patients [CDK6high (n = 17) vs. CDK6low (n = 18): p = 0.3] (cut point: median CDK6 expression level). (D) Kaplan–Meier analysis of OS in auto-/allo-HSCT group in cytogenetically normal AML patients [CDK6high (n = 17) vs. CDK6low (n = 18): p = 0.3] (cut point: median CDK6 expression level). (E) The survival analysis of probe 243000_at of 162 cytogenetically normal AML (CN-AML) patients using the online web tool GenomicScape (cut point: 596.34, p = 0.0036, HR = 1.8); (F) the survival analysis of probe 207143_at of 162 cytogenetically normal AML (CN-AML) patient (cut point: 337.79, p = 0.048, HR = 1.6). (G) The survival analysis of probe 235287_at of 78 cytogenetically normal AML (CN-AML) patients using the online web tool Genomicscape (cut off: 596.34, p = 0.033, HR = 2). (H) The survival analysis of probe 235287_at of 162 cytogenetically normal AML (CN-AML) patients using the online web tool Genomicscape (cut point: 596.34, p = 0.0055, HR = 1.8).